RT Journal Article
SR Electronic
T1 Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 4S
OP 11S
DO 10.2967/jnumed.123.266983
VO 65
IS Supplement 1
A1 Zhao, Liang
A1 Kang, Fei
A1 Pang, Yizhen
A1 Fang, Jianyang
A1 Sun, Long
A1 Wu, Hua
A1 Lan, XiaoLi
A1 Wang, Jing
A1 Chen, Haojun
YR 2024
UL http://jnm.snmjournals.org/content/65/Supplement_1/4S.abstract
AB Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China’s engagement with FAPI tracers, aiming to guide future research endeavors.